Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07223411 · ClinicalTrials.gov registry record
Opdualag vs. Cemiplimab/Fianlimab in Relation to the Immunological Response in Tumor and Peripheral Blood in Unresectable or Metastatic Melanoma
A clinical trial of Locally Advanced Melanoma, sponsored by John Kirkwood.
- Recruiting
- Registry status
- 20
- Enrollment target
- 1
- Study location
NCT07223411 is a study of Locally Advanced Melanoma that is actively recruiting participants, run by John Kirkwood. The registered enrollment target is 20 participants, below the 123-participant average among 5 other Locally Advanced Melanoma trials with a reported enrollment target (84% lower). The trial reports 1 study location across 1 state.
The verdict
NCT07223411, a study of Locally Advanced Melanoma, is actively recruiting participants, sponsored by John Kirkwood.
- RECRUITING
- Registry status
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
This translational study will examine the immune effector responses of patients who received a two-drug combination for first line therapy by examining tumor and peripheral blood of participants with unresectable locally advanced or metastatic melanoma.
Conditions Studied
Interventions
- DRUG Fianlimab + Cemiplimab
- DRUG Relatlimab + Nivolumab
Study Locations (1)
Pennsylvania
- UPMC Hillman Cancer Center - Pittsburgh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2025-11-19 |
| Est. Completion | 2031-11-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07223411
The ClinicalTrials.gov registry entry for NCT07223411 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 123-participant average among 5 other Locally Advanced Melanoma trials with a reported enrollment target (84% lower). The listed sponsor is John Kirkwood, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Locally Advanced Melanoma appearing as the primary indexed condition, and to 2 interventions - of which Fianlimab + Cemiplimab is the first listed.
NCT07223411 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT07223411 about?
NCT07223411 is a clinical study titled "Opdualag vs. Cemiplimab/Fianlimab in Relation to the Immunological Response in Tumor and Peripheral Blood in Unresectable or Metastatic Melanoma". This translational study will examine the immune effector responses of patients who received a two-drug combination for first line therapy by examining tumor and peripheral blood of participants with unresectable locally advanced or metastatic melanoma.
What is the current status of trial NCT07223411?
This trial is currently recruiting. The enrollment target is 20 participants. The study started on 2025-11-19. Estimated completion is 2031-11-01.
What conditions does trial NCT07223411 study?
This clinical trial studies the following conditions: Locally Advanced Melanoma.
What interventions are being tested in trial NCT07223411?
The interventions under investigation include: Fianlimab + Cemiplimab (DRUG), Relatlimab + Nivolumab (DRUG).
Who is sponsoring clinical trial NCT07223411?
This trial is sponsored by John Kirkwood, which has 8 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07223411 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Locally Advanced Melanoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing
RECRUITING · Phase 1
-
Evaluation of Anti-PD-1 Therapy by Monitoring T Cell Responses in Melanoma, Lung and Other Cancer Types
RECRUITING
-
Avapritinib for the Treatment of CKIT or PDGFRA Mutation-Positive Locally Advanced or Metastatic Malignant Solid Tumors
RECRUITING · Phase 2
-
Neoadj Admin Autologous Tumor Infiltrating Lymphocytes & Pembrolizumab for Treatment of Adv Melanoma Patients
ACTIVE NOT RECRUITING · Phase 1
-
Abexinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumor Malignancies
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.